Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exscientia Ltd ADR
(NQ:
EXAI
)
5.050
-0.220 (-4.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
682,914
Open
5.140
Bid (Size)
5.000 (12)
Ask (Size)
5.250 (14)
Prev. Close
5.270
Today's Range
5.020 - 5.270
52wk Range
3.800 - 7.910
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
August 08, 2024
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 08, 2024
Operational complementarities expected to yield annual synergies of approximately $100 million
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-19.26%
-19.26%
1 Month
-9.17%
-9.17%
3 Month
+2.85%
+2.85%
6 Month
-32.76%
-32.76%
1 Year
-24.17%
-24.17%
More News
Read More
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
Via
Talk Markets
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
Via
Talk Markets
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
July 18, 2024
From
Exscientia plc
Via
Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
Via
Talk Markets
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
July 10, 2024
From
Exscientia plc
Via
Business Wire
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Via
Talk Markets
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 25, 2024
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
June 24, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
June 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 24, 2024
From
The Schall Law Firm
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm
June 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
June 21, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
June 21, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 21, 2024
From
Schall Law
Via
GlobeNewswire
EXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
June 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 18, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoodRx, Exscientia, Malibu Boats, and Equinix and Encourages Investors to Contact the Firm
June 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
Via
Talk Markets
Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
June 17, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
EXSCIENTIA PLC (NASDAQ: EXAI) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Exscientia plc
June 17, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Rosen Law Firm Urges Exscientia p.l.c. (EXAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
June 15, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.